Heron Therapeutics Inc (NASDAQ: HRTX) closed the day trading at $2.95 down -0.34% from the previous closing price of $2.96. In other words, the price has decreased by -$0.0100 from its previous closing price. On the day, 2006756 shares were traded.
Ratios:
For a better understanding of HRTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 2.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 13, 2024, Reiterated its Buy rating but revised its target price to $5 from $4 previously.
On May 27, 2020, Guggenheim started tracking the stock assigning a Buy rating and target price of $24.
Needham reiterated its Buy rating for the stock on February 20, 2020, while the target price for the stock was revised from $50 to $48.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’23 when Forbes William P bought 25,000 shares for $1.09 per share. The transaction valued at 27,250 led to the insider holds 79,000 shares of the business.
Collard Craig A bought 150,000 shares of HRTX for $137,970 on Nov 16 ’23. The Chief Executive Officer now owns 186,496 shares after completing the transaction at $0.92 per share. On Nov 16 ’23, another insider, Duarte Ira, who serves as the EVP, Chief Financial Officer of the company, bought 85,000 shares for $0.89 each. As a result, the insider paid 75,599 and bolstered with 85,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HRTX now has a Market Capitalization of 445.72M and an Enterprise Value of 544.94M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.49. Its current Enterprise Value per Revenue stands at 4.29 whereas that against EBITDA is -5.25.
Stock Price History:
The Beta on a monthly basis for HRTX is 1.68, which has changed by 49.75% over the last 52 weeks, in comparison to a change of 31.54% over the same period for the S&P500. Over the past 52 weeks, HRTX has reached a high of $3.22, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is 2.5190, while the 200-Day Moving Average is calculated to be 1.5806.
Shares Statistics:
Over the past 3-months, HRTX traded about 3.14M shares per day on average, while over the past 10 days, HRTX traded about 4.18M shares per day. A total of 150.29M shares are outstanding, with a floating share count of 142.74M. Insiders hold about 5.05% of the company’s shares, while institutions hold 71.22% stake in the company. Shares short for HRTX as of Feb 29, 2024 were 24.53M with a Short Ratio of 7.82, compared to 24.33M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 16.35% and a Short% of Float of 18.83%.
Earnings Estimates
Current recommendations for the stock of the company come from 2 analysts. On average, analysts expect EPS of -$0.09 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.11, while EPS last year was -$0.27. The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.05 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.2 and -$0.79 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is -$0.36, with 3 analysts recommending between -$0.02 and -$0.91.
Revenue Estimates
3 analysts predict $32.8M in revenue for the current quarter. It ranges from a high estimate of $34.4M to a low estimate of $30.9M. As of the current estimate, Heron Therapeutics Inc’s year-ago sales were $29.61M, an estimated increase of 10.80% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $34.37M, an increase of 8.20% less than the figure of $10.80% in the same quarter last year. There is a high estimate of $37.1M for the next quarter, whereas the lowest estimate is $32.3M.
A total of 3 analysts have provided revenue estimates for HRTX’s current fiscal year. The highest revenue estimate was $151.3M, while the lowest revenue estimate was $138M, resulting in an average revenue estimate of $145.93M. In the same quarter a year ago, actual revenue was $127.04M, up 14.90% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $175.5M in the next fiscal year. The high estimate is $180.3M and the low estimate is $171.2M. The average revenue growth estimate for next year is up 20.30% from the average revenue estimate for this year.
